These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 10688083

  • 1. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
    Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A.
    Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
    Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A.
    Urology; 2000 Aug 01; 56(2):228-31. PubMed ID: 10925083
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Aug 01; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug 01; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 5. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
    Sánchez-Carbayo M, Urrutia M, Hernández-Cerceño ML, González de Buitrago JM, Navajo JA.
    Med Clin (Barc); 2000 Mar 18; 114(10):361-6. PubMed ID: 10786344
    [Abstract] [Full Text] [Related]

  • 6. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E.
    BJU Int; 2001 Nov 18; 88(7):692-701. PubMed ID: 11890239
    [Abstract] [Full Text] [Related]

  • 7. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M.
    J Urol; 1998 Jun 18; 159(6):1876-80. PubMed ID: 9598479
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S, Biri H, Sinik Z, Küpeli B, Alkibay T, Bozkirli I.
    Eur Urol; 1999 Sep 18; 36(3):225-9. PubMed ID: 10450007
    [Abstract] [Full Text] [Related]

  • 9. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I.
    Int J Med Sci; 2017 Sep 18; 14(9):811-819. PubMed ID: 28824318
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
    Lee KH.
    Yonsei Med J; 2001 Feb 18; 42(1):14-8. PubMed ID: 11293494
    [Abstract] [Full Text] [Related]

  • 11. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar 18; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 12. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
    Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.
    J Urol; 1996 Aug 18; 156(2 Pt 1):363-7. PubMed ID: 8683680
    [Abstract] [Full Text] [Related]

  • 13. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug 18; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer.
    Oge O, Atsü N, Kendi S, Ozen H.
    Int Urol Nephrol; 2001 Aug 18; 32(3):367-70. PubMed ID: 11583354
    [Abstract] [Full Text] [Related]

  • 15. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R, Huber P, Blöchlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K.
    J Urol; 2000 Dec 18; 164(6):1926-8. PubMed ID: 11061883
    [Abstract] [Full Text] [Related]

  • 16. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM.
    Asian Pac J Cancer Prev; 2010 Dec 18; 11(5):1279-82. PubMed ID: 21198277
    [Abstract] [Full Text] [Related]

  • 17. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD, Dudderidge TJ, Wollenschlaeger A, Okoturo O, Burling K, Tulloch F, Halsall I, Prevost T, Prevost AT, Vasconcelos JC, Robson W, Leung HY, Vasdev N, Pickard RS, Williams GH, Stoeber K.
    PLoS One; 2012 Dec 18; 7(7):e40305. PubMed ID: 22792272
    [Abstract] [Full Text] [Related]

  • 18. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
    Mungan NA, Vriesema JL, Thomas CM, Kiemeney LA, Witjes JA.
    Urology; 2000 Nov 01; 56(5):787-92. PubMed ID: 11068302
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
    Chahal R, Darshane A, Browning AJ, Sundaram SK.
    Eur Urol; 2001 Oct 01; 40(4):415-20; discussion 421. PubMed ID: 11713396
    [Abstract] [Full Text] [Related]

  • 20. A study comparing various noninvasive methods of detecting bladder cancer in urine.
    Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC.
    BJU Int; 2002 Mar 01; 89(4):369-73. PubMed ID: 11872026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.